MedPath

Chi-Myst Synergy

Chi-Myst Synergy Topical

Approved
Approval ID

503f8f9b-595f-4f0b-8ea0-c45cf4f64632

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 13, 2017

Manufacturers
FDA

Prescription Care LLC

DUNS: 080059076

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Chitosan ketorolac bupivacaine lidocaine suspension

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70486-030
Product Classification
G
Generic Name
Chitosan ketorolac bupivacaine lidocaine suspension
Product Specifications
Route of AdministrationTOPICAL
Effective DateJanuary 13, 2017
FDA Product Classification

INGREDIENTS (8)

CHITOSAN LOW MOLECULAR WEIGHT (20-200 MPA.S)Active
Quantity: 0.03 g in 30 mL
Code: SBD1A2I75N
Classification: ACTIB
KETOROLAC TROMETHAMINEActive
Quantity: 0.45 g in 30 mL
Code: 4EVE5946BQ
Classification: ACTIM
GLYCERINInactive
Quantity: 0.3 mL in 30 mL
Code: PDC6A3C0OX
Classification: IACT
WATERInactive
Quantity: 30 mL in 30 mL
Code: 059QF0KO0R
Classification: IACT
LACTIC ACID LACTATE, DL-Inactive
Quantity: 0.042 mL in 30 mL
Code: N37QW3EK1L
Classification: IACT
SODIUM HYDROXIDEInactive
Quantity: 0.01950 g in 30 mL
Code: 55X04QC32I
Classification: IACT
LIDOCAINE HYDROCHLORIDEActive
Quantity: 1.5 g in 30 mL
Code: V13007Z41A
Classification: ACTIR
BUPIVACAINE HYDROCHLORIDEActive
Quantity: 0.09 g in 30 mL
Code: 7TQO7W3VT8
Classification: ACTIR

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Chi-Myst Synergy - FDA Drug Approval Details